FARMINGTON, Conn., Oct. 31, 2012 /PRNewswire-iReach/ -- Learn about the global market for progressive ataxia and weakness disorder treatments and the factors that will influence the long-term development of neurodegenerative disorders in the pharmaceutical and biotechnology markets; learn about the treatments that are most likely to be commercialized in the next five years.
Pharmaceutical biotechnical companies, research institutes and physicians will find these new studies to be of interest.
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.
Key areas of growth in the neurodegenerative disorder market include: Friedreich's ataxia, Gerstmann-Straussler-Scheinker disease, Machado-Joseph disease, amyotrophic lateral sclerosis, progressive bulbar palsy, hereditary spastic paraplegia, hereditary neuropathies and multiple sclerosis.
The report discusses applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology. The report also covers significant patents and their allotments in each category.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/bc252617-global-markets-treatments-syndromes-progressive.html
Focus on Progressive Ataxia
Progressive ataxia treatments are expected to be valued at $356.4 million in 2012 and $620.7 million in 2017 at a CAGR of 11.7%. Treatments for Machado-Joseph disease should total $158.4 million in 2012 and $273.5 million in 2017, a CAGR of 11.5%.
This report explores present and future strategies within the progressive ataxia and weakness disorders market, which includes treatments and therapies for dysfunctions, including progressive ataxia and progressive weakness disorder syndromes. The market's improvisation, setbacks and needs are also discussed. The comparisons, usage, advantages and disadvantages of different types of technologies, including small-molecule and monoclonal antibodies, are also presented.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/bc252845-global-markets-treatments-syndromes-progressive.html
Focus on Weakness Disorders
Treatments for progressive weakness syndromes should total nearly $14.6 billion in 2012 and $22.8 billion in 2017 at a CAGR of 9.4%. Treatments for multiple sclerosis should total nearly $12.6 billion in 2012 and $19.5 billion in 2017, a CAGR of 9.2%.
This report includes a detailed analysis of the industry structure with revenues broken down by the neurodegenerative dysfunction. Sales figures are estimated for the five-year period from 2012 through 2017.
Executives can use this report to identify segments of the global market for weakness disorders with the greatest commercial potential through 2017; project future demand of treatments; evaluate challenges that must be overcome; and gain information on relevant patents as well as major players involved in the industry.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/bc252846-global-markets-treatments-syndromes-progressive.html
Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Movement Disorders
The global market for treatments for syndromes of dementia and movement disorders was valued at $10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%. Treatments for movement disorders are expected to be worth $3.2 billion in 2012 and $4.8 billion in 2017, a CAGR of 8.3%. Sales of Parkinson's drugs used to treat movement disorder syndromes are expected to have a value of $2.9 billion in 2012 and nearly $4.3 billion in 2017, a CAGR of 8.1%.
This report explores present and future strategies within the neurodegenerative disorder market, which includes treatments and therapies for progressive dementia, progressive dementia with other neurological abnormalities and movement disorders. Market gains, setbacks and needs are discussed in this report. Comparisons, usage and the advantages and disadvantages of different types of technologies, including small molecules and monoclonal antibodies, are also presented in this report.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/bc251478-global-markets-treatments-dementia-movement.html
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.Media Contact:
Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Global Information, Inc.